Radiation therapy for prostate cancer in the new S3 guideline - Part 1: localized and locally advanced prostate cancer

被引:0
|
作者
Boehmer, D. [1 ]
Wenz, F. [2 ]
Martin, T. [3 ]
Sedlmayr, F. [4 ]
Hinkelbein, W. [5 ]
Wiegel, T. [6 ]
机构
[1] Charite, Klin Strahlentherapie, D-13353 Berlin, Germany
[2] Univ Klinikum Mannheim, Mannheim, Germany
[3] Praxisgemeinschaft Strahlentherapie & Radioonkol, Bremen, Germany
[4] Salzburger Landeskliniken, Klin Radiotherapie & Radioonkol, Salzburg, Austria
[5] Charite, Klin Radioonkol & Strahlentherapie, D-13353 Berlin, Germany
[6] Univ Ulm Klinikum, Klin Strahlentherapie & Radioonkol, Ulm, Germany
来源
UROLOGE | 2010年 / 49卷 / 02期
关键词
S3; guideline; Prostate cancer; Radiation therapy; Hormone therapy; INTENSITY-MODULATED RADIOTHERAPY; ANDROGEN SUPPRESSION; CONFORMAL RADIOTHERAPY; DOSE-ESCALATION; RADICAL PROSTATECTOMY; TRIAL; NEOADJUVANT; IRRADIATION; CARCINOMA; TOXICITY;
D O I
10.1007/s00120-010-2241-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Radiation therapy is a treatment option for curative management of localized and locally advanced prostate cancer. Depending on tumor stage and constellation of risk factors (PSA level, findings on digital rectal examination, and Gleason score), various forms of radiotherapy are applied. In addition to the sole use of external beam radiotherapy, brachytherapy with radioactive seeds is also employed as stand-alone treatment in patients with low risk factors and in early clinical stages. Increasing risk of recurrence requires more intensive therapies which can be accomplished by adding hormone deprivation therapy and/or intensifying radiation therapy (dose escalation). Combined approaches using brachytherapy and percutaneous radiotherapy are also initiated in these cases. If hormone ablation therapy is administered, this should occur over a course of 3-36 months as neoadjuvant, concommitant and/or adjuvant treatment, depending on the risk of recurrence.
引用
收藏
页码:211 / 215
页数:5
相关论文
共 50 条